Abyssinia Expeditionary Force IOR/L/MIL/5/652
0000 - Gale Group | NCCO EuropeAfrica
Jennifer M. Meyers, Rytis Prekeris,
... pEGFP-N3 vector (Clontech). cDNA encoding Rip11 (490–652) was fused to the N terminus of pEGFP- ... important for Rab11 binding, we created Rip11 (490–652), FIP2 (378–511), and Eferin (665–759) truncation ... predicted α-helix. CD analysis of Rip11 (490–652) (Fig. 2, D,F, and G) and FIP2 ( ... binding to Rab11, we incubated GST-Rip11 (490–652)-coated glutathione beads with increasing concentrations of soluble ... 5 μm) but not Rab4. Furthermore, Rip11 (490–652) binding to Rab11 was GTP-dependent (Fig. 1B, inset), compared with Rip11 (630–652), which contains only the RBD domain (19Prekeris R. ...
Tópico(s): Retinal Development and Disorders
2002 - Elsevier BV | Journal of Biological Chemistry
Abyssinia Expeditionary Force IOR/L/MIL/5/652 Government document. From C. W. White Lt. Colonel. Mahableshwar.
0000 - Gale Group | NCCO EuropeAfrica
... study.Hepatology. 2002; 36: 451-455Crossref PubMed Scopus (652) Google Scholar]. Sgro et al. [[4]Sgro C. ... study.Hepatology. 2002; 36: 451-455Crossref PubMed Scopus (652) Google Scholar] studied drug-induced liver injury diagnosed ... study.Hepatology. 2002; 36: 451-455Crossref PubMed Scopus (652) Google Scholar] supports the Spanish finding [[3]Ibáñez ... study.Hepatology. 2002; 36: 451-455Crossref PubMed Scopus (652) Google Scholar]. This estimate is very close to ... study.Hepatology. 2002; 36: 451-455Crossref PubMed Scopus (652) Google Scholar] studies, the definitions of drug-induced ...
Tópico(s): Drug Transport and Resistance Mechanisms
2002 - Elsevier BV | Journal of Hepatology
Abyssinia Expeditionary Force IOR/L/MIL/5/652
0000 - Gale Group | NCCO EuropeAfrica
... raloxifene and tamoxifen acutely relax coronary arteries. EM-652 (SCH 57068) is a 4th generation SERM acting ... the present study, the vascular effects of EM-652 and E2 on the rat mesentery were investigated. ... Increasing doses (0.1-10 microM) of EM-652 or E2 were infused into the perfusate.EM-652 and E2 relaxed MVBs removed from intact and ... female and male rats. The amplitude of EM-652 responses was consistently greater than those of E2 ... or greater than that of other SERMs. EM-652 and E2 relaxed MVB by an endothelium-independent ...
Tópico(s): Inflammatory mediators and NSAID effects
2003 - Oxford University Press | Cardiovascular Research
Abyssinia Expeditionary Force IOR/L/MIL/5/652 Government document. From C. W. White Lieutt. Colonel. Mahableshwar.
0000 - Gale Group | NCCO EuropeAfrica
Valérie Perrot, Matthew M. Rechler,
... C-terminal fragment of Foxo1 (amino acids 208–652) containing the transactivation domain is fused to the ... rat hepatoma cells. Insulin inhibition of Foxo1-(208–652)-stimulated transactivation is mediated by PI 3-kinase ... for insulin inhibition of transactivation by Foxo1-(208–652). We conclude that the transcriptional activity of Foxo1 ... C-terminal fragment of Foxo1 (amino acids 208–652) containing the transactivation domain is fused to the ... rat hepatoma cells. Insulin inhibition of Foxo1-(208–652)-stimulated transactivation is mediated by PI 3-kinase ...
Tópico(s): FOXO transcription factor regulation
2003 - Elsevier BV | Journal of Biological Chemistry
Abyssinia Expeditionary Force IOR/L/MIL/5/652
0000 - Gale Group | NCCO EuropeAfrica
Christian Lemieux, Frédéric Picard, Fernand Labrie, Denis Richard, Yves Deshaies,
Abstract Objective : EM‐652 is a pure antiestrogen in human breast and uterine cancer cells that also reduces bone loss and plasma lipid ... study aimed to assess the ability of EM‐652, alone or with dehydroepiandrosterone (DHEA), to prevent obesity ... or ovariectomized (OVX), and were treated with EM‐652, DHEA, or both for 20 days. Variables of ... gain, as well as energetic efficiency. Both EM‐652 and DHEA prevented diet‐ and OVX‐induced energy ... fat deposition, without being additive. The modest EM‐652‐induced increase in liver triglycerides of intact rats ...
Tópico(s): Cancer Risks and Factors
2003 - Wiley | Obesity Research
PubMed Central (PMC)
Abyssinia Expeditionary Force IOR/L/MIL/5/652 Government document. Camp Zoolla.
0000 - Gale Group | NCCO EuropeAfrica
Elena Silvano, Mark J. Millan, Clotilde Mannoury la Cour, Yang Han, Lihua Duan, Suzy A. Griffin, Robert R. Luedtke, Gabriella Aloisi, Mario Rossi, Francesca Zazzeroni, Jonathan A. Javitch, Roberto Maggio,
... H -isoquinolin-2-yl)-ethyl]-cyclohexyl}-amide (SB269,652) behaves as an atypical, allosteric antagonist at D 3 and D 2 receptors. Accordingly, SB269,652 potently (low nanomolar range) abolished specific binding of [ ... However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these ... 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D 3 receptor-mediated activation of ... fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gα ...
Tópico(s): Neurotransmitter Receptor Influence on Behavior
2010 - American Society for Pharmacology and Experimental Therapeutics | Molecular Pharmacology
Abyssinia Expeditionary Force IOR/L/MIL/5/652
0000 - Gale Group | NCCO EuropeAfrica
... Identification of a ssDNA-binding activity in Sgs11−652 (A) Schematic representations of the full-length 1447 aa Sgs1 protein and Sgs11−652. Domains: TR, Top3–Rmi1 binding; B, C-terminal ... contained the indicated concentrations of His6-tagged Sgs11−652 and 1 nM of either primed ssDNA (oligo # ... agarose gels followed by phosphorimager analysis. (C) Sgs11−652 (300 nM) was incubated together with 1 nM ... Sgs1 protein. (D) The indicated concentrations of Sgs11−652 were incubated with one of three 32P-labelled ... Supplementary Figure S1B). In yeast, this domain (Sgs11−652) is known to be physiologically important (Mullen et ...
Tópico(s): Genomics and Chromatin Dynamics
2010 - Springer Nature | The EMBO Journal
IEEE Xplore
Abyssinia Expeditionary Force IOR/L/MIL/5/652 Government document. From F. J. Marriott Colonel. To Lieutt. Genl. Sir R. Napier R. C. B. Simla.
0000 - Gale Group | NCCO EuropeAfrica
Bing‐bing Zhang, Ganesan Ramesh, Christopher C. Norbury, William Reeves,
... Clin Invest. 2002; 110: 835-842Crossref PubMed Scopus (652) Google Scholar,3Ramesh G. Reeves W.B. TNFR2- ... Clin Invest. 2002; 110: 835-842Crossref PubMed Scopus (652) Google Scholar Specifically, genetic deletion of TNF-α ... Clin Invest. 2002; 110: 835-842Crossref PubMed Scopus (652) Google Scholar, 3Ramesh G. Reeves W.B. TNFR2- ... Clin Invest. 2002; 110: 835-842Crossref PubMed Scopus (652) Google Scholar GFR was also determined by fluorescein ... Clin Invest. 2002; 110: 835-842Crossref PubMed Scopus (652) Google Scholar Accordingly, we examined the expression of ...
Tópico(s): Acute Kidney Injury Research
2007 - Elsevier BV | Kidney International
Abyssinia Expeditionary Force IOR/L/MIL/5/652 Memorandum. From Fred. Thesiger.
0000 - Gale Group | NCCO EuropeAfrica
Atsushi Sofuni, Hiroyuki Maguchi, Takao Itoi, Akio Katanuma, Hiroyuki Hisai, Teitetsu Niido, Masayuki Toyota, Tsuneshi Fujii, Youji Harada, Tadanori Takada,
... after performance of ERCP.Gastrointest Endosc. 2002; 56: 652-656Abstract Full Text Full Text PDF PubMed Scopus ( ... in high-risk patients.Gastrointest Endosc. 1993; 39: 652-657Abstract Full Text PDF PubMed Scopus (191) Google ... after performance of ERCP.Gastrointest Endosc. 2002; 56: 652-656Abstract Full Text Full Text PDF PubMed Scopus ( ... in high-risk patients.Gastrointest Endosc. 1993; 39: 652-657Abstract Full Text PDF PubMed Scopus (191) Google ... after performance of ERCP.Gastrointest Endosc. 2002; 56: 652-656Abstract Full Text Full Text PDF PubMed Scopus ( ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2007 - Elsevier BV | Clinical Gastroenterology and Hepatology
Abyssinia Expeditionary Force IOR/L/MIL/5/652
0000 - Gale Group | NCCO EuropeAfrica
Jean‐François Marier, MyMy Trinh, L.H. Pheng, Sandra M. Palleja, David E. Martin,
TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of this study ... the pharmacokinetics (PK) and pharmacodynamics (PD) of TBR-652 in HIV-1-infected, antiretroviral treatment-experienced, CCR5 ... placebo-controlled, randomized, dose-escalating study of TBR-652 monotherapy given once daily orally for 10 days ... 25, 50, 75, 100, and 150 mg TBR-652 or placebo (4:1). Blood was collected at ... HIV-1 RNA assessments. PK analysis of TBR-652 was performed using noncompartmental methods. PK/PD was ...
Tópico(s): Pneumocystis jirovecii pneumonia detection and treatment
2011 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy